Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

CRISPR Therapeutics (CRSP) Surges: Stock Moves 6.8% Higher

ZUG, Switzerland and CAMBRIDGE, Mass., June  30, 2020  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 964,285 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $450.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 6, 2020, subject to customary closing conditions.

CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares

ZUG, Switzerland and CAMBRIDGE, Mass., June  29, 2020  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of common shares. In addition, the underwriters will have a 30-day option to purchase up to an additional $48,750,000 of common shares at the public offering price less the underwriting discount.

CRISPR Therapeutics Announces Proposed Offering of Common Shares

Crispr Therapeutics AG: Risks, Rewards, And Valuation

bluebird bio

Both of these biotech companies recently released encouraging data from clinical trials.

2 Top Gene-Editing Stocks to Buy Right Now

Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.

The Future Could Be Soon for Crispr Therapeutics

Two bullish analyst recommendations in less than 24 hours boost the stock price more than 9%.

Why CRISPR Therapeutics Stock Just Popped Another 5%

CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.

3 Reasons to Go Long Crispr Therapeutics

Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
The post CRISPR Therapeutics Is a Worthwhile Investment in Transformative Science appeared first on InvestorPlace.

CRISPR Therapeutics Is a Worthwhile Investment in Transformative Science

Dollar General

iShares 20+ Year Treasury Bond ETF

Vanguard Long-Term Treasury ETF

Vertex Pharmaceuticals

Even if the market goes down, these investing options should go up.

Where to Invest $1,000 If You're Worried the Stock Market Might Crash Again

Sangamo Therapeutics

Each company aims to use its genome editing platform to treat disease, but which has an edge?

Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics

The partners reported encouraging results from the first four patients treated with the CRISPR-based gene-editing therapy.

CRISPR Therapeutics and Vertex Pharmaceuticals Deliever New CTX001 Data

Crispr Therapeutics and Vertex Pharmaceuticals stocks popped Friday after the biotech companies unveiled updated results for a gene-editing drug in blood-disease treatment.
The post CRISPR Rally: The First Gene-Editing Drug Continues To Show Promise appeared first on Investor's Business Daily.

CRISPR Rally: The First Gene-Editing Drug Continues To Show Promise

-Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia-

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

Intellia Therapeutics

Which gene editing stock wins this matchup?

Better Buy: CRISPR Therapeutics vs. Intellia

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 22.9% Since Last Earnings Report?

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating

Fate Therapeutics

Here's what's behind two of the most exciting stocks in the gene therapy sector.

2 Top Gene Editing Stocks to Watch in June

Moderna

TG Therapeutics

By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.

The 3 Best Biotech Stocks to Own in 2020

Crispr Therapeutics saw its stock shoot up 15% in two days after Crispr and Vertex Pharmaceuticals gained a fast-track status for a new gene-editing drug.
The post Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-Tracked appeared first on Investor's Business Daily.

Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-Tracked

One of the company's pipeline candidates received the orphan drug designation from the FDA.

Why CRISPR Therapeutics Soared 13.8% Today

CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

Who wins in a matchup between these two gene-editing leaders?

Better Buy: Crispr Therapeutics vs. bluebird bio

Gilead Sciences

Galapagos

Incyte

Neurocrine Biosciences

Regeneron Pharmaceuticals

Acceleron Pharma

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

7 Beautiful Biotech Stocks to Buy Here

Global Blood Therapeutics

Novartis

Targeted therapies for treating sickle cell disease are finally here after a 60-year wait.

News for CRISPR Therapeutics Stock (CRSP)